Personal CFO Solutions LLC Buys New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Personal CFO Solutions LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,242 shares of the biopharmaceutical company's stock, valued at approximately $207,000.

A number of other large investors have also added to or reduced their stakes in the company. Atlantic Union Bankshares Corp increased its stake in Gilead Sciences by 2.0% in the 4th quarter. Atlantic Union Bankshares Corp now owns 107,697 shares of the biopharmaceutical company's stock worth $9,948,000 after acquiring an additional 2,110 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its stake in Gilead Sciences by 1.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 13,743 shares of the biopharmaceutical company's stock worth $1,269,000 after acquiring an additional 209 shares during the last quarter. Rialto Wealth Management LLC bought a new stake in Gilead Sciences in the 4th quarter worth approximately $92,000. Lifeworks Advisors LLC increased its stake in Gilead Sciences by 6.9% in the 4th quarter. Lifeworks Advisors LLC now owns 82,434 shares of the biopharmaceutical company's stock worth $7,614,000 after acquiring an additional 5,315 shares during the last quarter. Finally, Larson Financial Group LLC increased its stake in Gilead Sciences by 17.5% in the 4th quarter. Larson Financial Group LLC now owns 9,205 shares of the biopharmaceutical company's stock worth $850,000 after acquiring an additional 1,370 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Wolfe Research started coverage on Gilead Sciences in a report on Friday, November 15th. They issued an "outperform" rating and a $110.00 target price for the company. Mizuho lifted their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Remove Ads

Gilead Sciences Price Performance

Shares of GILD stock opened at $114.43 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The stock has a market capitalization of $142.50 billion, a price-to-earnings ratio of 309.27, a P/E/G ratio of 0.71 and a beta of 0.21. The stock has a fifty day simple moving average of $100.56 and a two-hundred day simple moving average of $92.18. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.76%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 293,356 shares of company stock valued at $29,166,240. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.